BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Couvineau A, Dayot S, Nicole P, Gratio V, Rebours V, Couvelard A, Voisin T. The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. Front Endocrinol (Lausanne) 2018;9:573. [PMID: 30319552 DOI: 10.3389/fendo.2018.00573] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ball HL, Said H, Chapman K, Fu R, Xiong Y, Burk JA, Rosenbaum D, Veneziano R, Cotten ML. Orexin A, an amphipathic α-helical neuropeptide involved in pleiotropic functions in the nervous and immune systems: Synthetic approach and biophysical studies of the membrane-bound state. Biophysical Chemistry 2023. [DOI: 10.1016/j.bpc.2023.107007] [Reference Citation Analysis]
2 Wu Y, Berisha A, Borniger JC. Neuropeptides in Cancer: Friend and Foe? Adv Biol (Weinh) 2022;6:e2200111. [PMID: 35775608 DOI: 10.1002/adbi.202200111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Couvineau A, Nicole P, Gratio V, Voisin T. The Orexin receptors: Structural and anti-tumoral properties. Front Endocrinol 2022;13:931970. [DOI: 10.3389/fendo.2022.931970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Squillacioti C, Pelagalli A, Assisi L, Costagliola A, Van Nassauw L, Mirabella N, Liguori G. Does Orexin B-Binding Receptor 2 for Orexins Regulate Testicular and Epididymal Functions in Normal and Cryptorchid Dogs? Front Vet Sci 2022;9:880022. [DOI: 10.3389/fvets.2022.880022] [Reference Citation Analysis]
5 Voisin T, Nicole P, Gratio V, Chassac A, Mansour D, Rebours V, Couvelard A, Couvineau A. The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment. Front Oncol 2022;12:904327. [DOI: 10.3389/fonc.2022.904327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yates J, Barkmann F, Czyż P, Glettig M, Lohmann F, von der Horst R, Saquand E, Volken N, Kraft A, Boeva V. CanSig: Discovering de novo shared transcriptional programs in single cancer cells.. [DOI: 10.1101/2022.04.14.488324] [Reference Citation Analysis]
7 Fathima S, Murala S, Bollu PC. Orexins. Neurochemistry in Clinical Practice 2022. [DOI: 10.1007/978-3-031-07897-2_10] [Reference Citation Analysis]
8 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
9 Alain C, Pascal N, Valérie G, Thierry V. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules 2021;26:4849. [PMID: 34443437 DOI: 10.3390/molecules26164849] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Hasan MM, Alam MA, Shoombuatong W, Deng HW, Manavalan B, Kurata H. NeuroPred-FRL: an interpretable prediction model for identifying neuropeptide using feature representation learning. Brief Bioinform 2021:bbab167. [PMID: 33975333 DOI: 10.1093/bib/bbab167] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 16.5] [Reference Citation Analysis]
11 Selbach O. Orexins. Encyclopedia of Molecular Pharmacology 2021. [DOI: 10.1007/978-3-030-21573-6_208-1] [Reference Citation Analysis]
12 Vaughn CM, Vaughn BV. Cancer and sleep: is cancer a circadian rhythm disorder? Reference Module in Neuroscience and Biobehavioral Psychology 2021. [DOI: 10.1016/b978-0-12-822963-7.00088-8] [Reference Citation Analysis]
13 Mogavero MP, DelRosso LM, Fanfulla F, Bruni O, Ferri R. Sleep disorders and cancer: State of the art and future perspectives. Sleep Med Rev 2021;56:101409. [PMID: 33333427 DOI: 10.1016/j.smrv.2020.101409] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 9.7] [Reference Citation Analysis]
14 Li SB, de Lecea L. The hypocretin (orexin) system: from a neural circuitry perspective. Neuropharmacology 2020;167:107993. [PMID: 32135427 DOI: 10.1016/j.neuropharm.2020.107993] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
15 Couvineau A, Voisin T, Nicole P, Gratio V, Abad C, Tan YV. Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. Front Endocrinol (Lausanne) 2019;10:709. [PMID: 31695678 DOI: 10.3389/fendo.2019.00709] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
16 Kong T, Qiu K, Liu M, Cheng B, Pan Y, Yang C, Chen J, Wang C. Orexin-A protects against oxygen-glucose deprivation/reoxygenation-induced cell damage by inhibiting endoplasmic reticulum stress-mediated apoptosis via the Gi and PI3K signaling pathways. Cellular Signalling 2019;62:109348. [DOI: 10.1016/j.cellsig.2019.109348] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]